Plasma exchange with immunosuppression in pulmonary alveolar haemorrhage due to leptospirosis.
OBJECTIVE
Pulmonary involvement due to leptospirosis carries high case fatality rate and is the commonest cause of death due to leptospirosis. Immune mechanisms play a key role in the pathogenesis of leptospiral pulmonary haemorrhage. As other immune pulmonary haemorrhages due to non leptospiral causes are treated with plasma exchange and cyclophosphamide we evaluated their efficacy in patient with leptospiral pulmonary haemorrhage.


METHODS
Of the 602 confirmed patients of leptospirosis, 236 (39.2%) had pulmonary haemorrhage. Of these,144 had mild haemorrhage (acute lung injury score < 2.5) and were included in the study. One hundred and fourteen patients were given two cycles of plasma exchange, 24 h apart, 25 ml/kg body weight of plasma was removed in each cycle. Cyclophosphamide (20 mg/kg body weight) was given after the first plasma exchange cycle. The remaining 30 patients were not given this treatment, and used as control.


RESULTS
In the control group only 5 (16.6%) patients survived while in the treatment group 70 (61.40%) patients survived. Thrombocytopenia was observed in 111 (77.08%) patients. Renal and hepatic involvement was seen but did not account for mortality. Minor complications were seen in group I patients after plasma exchange and cyclophosphamide treatment, but none were serious.


CONCLUSIONS
Our findings showed that plasma exchange with immunosuppression improved survival in patients of pulmonary alveolar haemorrhage due to leptospirosis, suggesting that immune mechanisms play a key role in the pathogenesis of the disease.
Trivedi
Samir V
SV
Department of Medicine, Government Medical College, Surat, India. svt1212@yahoo.co.in
Vasava
Ashvin H
AH
Bhatia
Lovleen C
LC
Patel
Tinkal C
TC
Patel
Nimesh K
NK
Patel
Nehal T
NT
D000293:Adolescent; D000328:Adult; D003520:Cyclophosphamide / Q000494:pharmacology; D005260:Female; D006470:Hemorrhage / Q000209:etiology / Q000628:therapy*; D006801:Humans; D007107:Immune System; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D007922:Leptospirosis / Q000150:complications* / Q000628:therapy*; D008168:Lung / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010951:Plasma Exchange / Q000379:methods*; D011650:Pulmonary Alveoli / Q000473:pathology*; D013997:Time Factors; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D003520:Cyclophosphamide